Literature DB >> 9108084

Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts.

J Allison1, H M Georgiou, A Strasser, D L Vaux.   

Abstract

Binding of CD95 (Fas/APO-1) by its ligand (CD95L) commonly induces apoptosis. Apoptosis of activated T cells, induced by CD95L expressed in the rodent testis, has been proposed to be the mechanism of immune privilege [Bellgrau, D., Gold, D., Selawry, H., Moore, J., Franzusoff, A. & Duke, R. C. (1995) Nature (London) 377, 630-632]. To test whether CD95L could protect pancreatic islet grafts from rejection, we made transgenic mice expressing murine CD95L on their islet beta cells and transplanted fetal pancreata under the kidney capsules of allogeneic animals. Expression of CD95L failed to protect the grafts from rejection. However, transgenic mice developed a granulocytic infiltration in their pancreata. These results demonstrate a pro-inflammatory function of CD95L and suggest that expression of CD95L may not be sufficient to protect organ allografts.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9108084      PMCID: PMC20547          DOI: 10.1073/pnas.94.8.3943

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  20 in total

1.  Correlation of fetal kidney and testis congenic graft survival with reduced major histocompatibility complex burden.

Authors:  M B Statter; K J Fahrner; E M Barksdale; D E Parks; R A Flavell; P K Donahoe
Journal:  Transplantation       Date:  1989-04       Impact factor: 4.939

2.  Fetal pancreatic islet transplantation in H-2 disparate congenic mice.

Authors:  H M Georgiou; T E Mandel
Journal:  Transplant Proc       Date:  1986-04       Impact factor: 1.066

3.  Monoclonal antibody-mediated tumor regression by induction of apoptosis.

Authors:  B C Trauth; C Klas; A M Peters; S Matzku; P Möller; W Falk; K M Debatin; P H Krammer
Journal:  Science       Date:  1989-07-21       Impact factor: 47.728

Review 4.  Immunologically privileged sites.

Authors:  C F Barker; R E Billingham
Journal:  Adv Immunol       Date:  1977       Impact factor: 3.543

5.  Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes.

Authors:  D Hanahan
Journal:  Nature       Date:  1985 May 9-15       Impact factor: 49.962

6.  Bovine serum albumin density gradient isolation of rat pancreatic islets.

Authors:  S P Lake; J Anderson; J Chamberlain; S J Gardner; P R Bell; R F James
Journal:  Transplantation       Date:  1987-06       Impact factor: 4.939

7.  Activation interferes with the APO-1 pathway in mature human T cells.

Authors:  C Klas; K M Debatin; R R Jonker; P H Krammer
Journal:  Int Immunol       Date:  1993-06       Impact factor: 4.823

8.  Fetal and postnatal testis shows immunoprivilege as donor tissue.

Authors:  M B Statter; R P Foglia; D E Parks; P K Donahoe
Journal:  J Urol       Date:  1988-01       Impact factor: 7.450

9.  Diabetes in transgenic mice resulting from over-expression of class I histocompatibility molecules in pancreatic beta cells.

Authors:  J Allison; I L Campbell; G Morahan; T E Mandel; L C Harrison; J F Miller
Journal:  Nature       Date:  1988-06-09       Impact factor: 49.962

10.  Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand.

Authors:  T Takahashi; M Tanaka; C I Brannan; N A Jenkins; N G Copeland; T Suda; S Nagata
Journal:  Cell       Date:  1994-03-25       Impact factor: 41.582

View more
  52 in total

1.  Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape.

Authors:  N P Restifo
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

2.  Countering the 'counterattack' hypothesis.

Authors:  N P Restifo
Journal:  Nat Med       Date:  2001-03       Impact factor: 53.440

Review 3.  New approaches to inducing the death of alloreactive lymphocytes.

Authors:  S M Krams
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

Review 4.  Fas death receptor signalling: roles of Bid and XIAP.

Authors:  T Kaufmann; A Strasser; P J Jost
Journal:  Cell Death Differ       Date:  2011-09-30       Impact factor: 15.828

Review 5.  Fas (CD95, Apo-1) ligand gene transfer.

Authors:  S E Lamhamedi-Cherradi; Y Chen
Journal:  J Clin Immunol       Date:  2001-01       Impact factor: 8.317

Review 6.  Challenges and emerging technologies in the immunoisolation of cells and tissues.

Authors:  John T Wilson; Elliot L Chaikof
Journal:  Adv Drug Deliv Rev       Date:  2007-10-11       Impact factor: 15.470

Review 7.  The many roles of FAS receptor signaling in the immune system.

Authors:  Andreas Strasser; Philipp J Jost; Shigekazu Nagata
Journal:  Immunity       Date:  2009-02-20       Impact factor: 31.745

Review 8.  CD95 (Fas/APO-1)/CD95L in the gastrointestinal tract: fictions and facts.

Authors:  J Sträter; P Möller
Journal:  Virchows Arch       Date:  2003-02-11       Impact factor: 4.064

9.  Fas ligand-induced murine pulmonary inflammation is reduced by a stable decoy receptor 3 analogue.

Authors:  Mark A Wortinger; Joseph W Foley; Patrick Larocque; Derrick R Witcher; Michael Lahn; Joseph A Jakubowski; Andrew Glasebrook; Ho Yeong Song
Journal:  Immunology       Date:  2003-10       Impact factor: 7.397

10.  Localized immune tolerance from FasL-functionalized PLG scaffolds.

Authors:  Michael Skoumal; Kyle B Woodward; Hong Zhao; Feng Wang; Esma S Yolcu; Ryan M Pearson; Kevin R Hughes; Andrés J García; Lonnie D Shea; Haval Shirwan
Journal:  Biomaterials       Date:  2018-11-13       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.